Document is current
Any future updates will be listed below
-
Authors
Dias, Matheus H
Liudkovska, Vladyslava https://orcid.org/0000-0002-0078-1041
Montenegro Navarro, Jasmine https://orcid.org/0000-0001-5644-7758
Giebel, Lisanne
Champagne, Julien https://orcid.org/0000-0001-8460-858X
Papagianni, Chrysa https://orcid.org/0009-0002-0513-0763
Bleijerveld, Onno B https://orcid.org/0000-0002-9395-2347
Velds, Arno https://orcid.org/0000-0003-4333-8872
Agami, Reuven https://orcid.org/0000-0002-2848-2473
Bernards, René https://orcid.org/0000-0001-8677-3423
Cieśla, Maciej https://orcid.org/0000-0002-8460-1991
-
Funding
Funding for this research was provided by:
National Science Center (UMO-2021/43/B/NZ3/01177)
National Science Center (UMO-2022/46/E/NZ3/00141)
X-omics Initiative (Project 184.034.019)
Lixte Biotechnology Holdings (Rene R Bernards)
Dutch Cancer Society (Rene R Bernards)
Dutch Ministry of Health, Welfare and Sport (Rene R Bernards)
Oncode Institute (Rene R Bernards)
- License Information
-
More Information
Article History
Received: 18 August 2023
Revised: 15 March 2024
Accepted: 20 March 2024
First Online: 10 April 2024
Disclosure and competing interests statement
: RB received research funding from Lixte Biotechnology Holdings, the company that manufactures LB-100. Rene Bernards is also a member of the board of directors of Lixte Biotechnology Holdings Ltd. MHD is a shareholder of Lixte Biotechnology. RA is a member of the Advisory Editorial Board of EMBO Reports, which has no bearing on the editorial consideration of this article for publication. The remaining authors declare no competing interests.
